CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY

$39,622

from Department of Health and Human Services · National Institutes of Health

HER2-MEDIATED IMMUNOREGULATION AND THERAPY RESISTANCE IN GLIOBLASTOMA - PROJECT SUMMARY GLIOBLASTOMA (GBM) REMAINS THE MOST AGGRESSIVE PRIMARY BRAIN TUMOR, WITH LIMITED TREATMENT OPTIONS AND A MEDIAN SURVIVAL OF APPROXIMATELY 10 MONTHS. ALTHOUGH ERBB/HER-FAMILY SIGNALING HAS BEEN EXTENSIVELY STUDIED IN OTHER CANCERS, THE FUNCTIONAL AND IMMUNOLOGIC CONSEQUENCES OF HER2 SIGNALING SPECIFICALLY IN...
Description as recorded in the federal award record (cut at 400 characters).

Award ID: F31CA318007
Award type: PROJECT GRANT (B)
First obligated: Aug 11, 2026
Period starts: Feb 11, 2027
Place of performance: Cuyahoga County, Ohio 44195
Assistance listing: 93.398 CANCER RESEARCH MANPOWER
Amount means: Federal obligation for this grant, as of our last read Oct 13, 2026.

Open the full record on USAspending.gov More in Cuyahoga County

Copied from USAspending.gov. Where It Lands is not a government site and is not affiliated with USAspending.gov or the awarding agency.